Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of KDT-3594 in early Parkinson's disease (Japan)
jRCT2031210089Phase 2Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of matsupexole in Parkinson's disease (PD), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoints: Occurrence of adverse events and Plasma concentrations of KDT-3594 and its metabolites. Started May 2021; status: completed.
02
Drugs
matsupexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2031210089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210089.